

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number  
**WO 2005/035495 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 209/00**

(21) International Application Number:  
PCT/IB2004/051922

(22) International Filing Date:  
30 September 2004 (30.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1054/MUM/2003 8 October 2003 (08.10.2003) IN

(71) Applicant (for all designated States except US):  
**NICHOLAS PIRAMAL INDIA LIMITED** [IN/IN];  
100, Centrepont, Dr. Ambedkar Road, Parel, Mumbai,  
Maharashtra 400012 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAL, Bansi** [IN/IN];  
Quest Institute of Life Sciences, Nicholas Piramal India  
Ltd., Next to Marathon Galaxy, Off L.B.S., Marg, Mulund  
(West), Mumbai, Maharashtra 400080 (IN). **GAN-  
GOPADHYAY, Ashok, Kumar** [IN/IN]; Quest Institute  
of Life Sciences, Nicholas Piramal India Ltd., Next to  
Marathon Galaxy, Off L.B.S., Marg, Mulund (West),  
Mumbai, Maharashtra 400080 (IN). **RAO, Vaddlamudi, V.,  
S., V.** [IN/IN]; Quest Institute of Life Sciences, Nicholas  
Piramal India Ltd., Next to Marathon Galaxy, Off L.B.S.,  
Marg, Mulund (West), Mumbai, Maharashtra 400080 (IN).  
**GUPTA, Ravindra, Dattatraya** [IN/IN]; Quest Institute  
of Life Sciences, Nicholas Piramal India Ltd., Next to  
Marathon Galaxy, Off L.B.S., Marg, Mulund (West),  
Mumbai, Maharashtra 400080 (IN). **GOLE, Gopal,  
Vishnu** [IN/IN]; Quest Institute of Life Sciences, Nicholas  
Piramal India Ltd., Next to Marathon Galaxy, Off L.B.S.,  
Marg, Mulund (West), Mumbai, Maharashtra 400080 (IN).  
**KULKARNI-ALMEIDA, Asha** [IN/IN]; Quest Institute  
of Life Sciences, Nicholas Piramal India Ltd., Next to  
Marathon Galaxy, Off L.B.S., Marg, Mulund (West),

Mumbai, Maharashtra 400080 (IN). **KRISHNAN, Sridevi**  
[IN/IN]; Quest Institute of Life Sciences, Nicholas Piramal  
India Ltd., Next to Marathon Galaxy, Off L.B.S., Marg,  
Mulund (West), Mumbai, Maharashtra 400080 (IN). **PAN-  
ICKER, Radha, Bhaskar** [IN/IN]; Quest Institute of Life  
Sciences, Nicholas Piramal India Ltd., Next to Marathon  
Galaxy, Off L.B.S., Marg, Mulund (West), Mumbai,  
Maharashtra 400080 (IN). **PINTO DE SOUZA, Eleanor**  
[IN/IN]; Quest Institute of Life Sciences, Nicholas Piramal  
India Ltd., Next to Marathon Galaxy, Off L.B.S., Marg,  
Mulund (West), Mumbai, Maharashtra 400080 (IN).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE



(57) Abstract: This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds

are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.